Sex-related differences in the pharmacokinetics of oral ciprofloxacin

Journal of Clinical Pharmacology

Volumn 44, Issue 9, 2004, Pages 1012-1022

  Overholser, Brian R ^a   Kays, Michael B ^a,b   Forrest, Alan ^c   Sowinski, Kevin M ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Ciprofloxacin; Drug exposure; Oral pharmacokinetics; Sex differences

Indexed keywords

CIPROFLOXACIN;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; REGRESSION ANALYSIS; SEX DIFFERENCE; SINGLE DRUG DOSE;

ADULT; ALGORITHMS; ANTI-INFECTIVE AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIPROFLOXACIN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HALF-LIFE; HUMANS; MALE; MODELS, BIOLOGICAL; SEX CHARACTERISTICS; SPECTROMETRY, FLUORESCENCE; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 4143078042     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004266843     Document Type: Article

References (45)

1. Navas E: Problems associated with potential massive use of antimicrobial agents as prophylaxis or therapy of a bioterrorist attack. Clin Microbiol Infect 2002;8:534-539.
2. Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, et al: Anthrax as a biological weapon: medical and public health management. JAMA 1999;281:1735-1745.
3. Brook I: The prophylaxis and treatment of anthrax. Int J Antimicrob Agents 2002;20:320-325.
4. Tsai AC, Lurie P, Sehgal AR: An outbreak of web sites selling ciprofloxacin following an outbreak of anthrax by mail. Am J Med 2002;113:424-427.
5. Shepard CW, Soriano-Gabarro M, Zell ER, Hayslett J, Lukacs S, Goldstein S, et al: Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 2002;8:1124-1132.
6. Schwartz JB: The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003:42:107-121.
7. Meibohm B, Beierle I, Derendorf H: How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002;41:329-342.
8. Bertino JS, Nafziger AN: Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers. Antimicrob Agents Chemother 1996;40:789-791.
9. Sawada M, Saishu Y, Hayashi SL: Post-marketing surveillance of levofloxacin in Japan [abstract]. Can J Infect Dis 1995;6:385C.
10. Pernet AG: Temafloxacin: a safe antibiotic for the elderly, patients with comorbidities, and other special populations. Am J Med 1991;91:162S-165S.
11. Stahlmann R, Lode H: Toxicity of quinolones. Drugs 1999;58:37-42.
12. Hoffler D, Dalhoff A, Gau W, Beermann D, Michl A: Dose- and sex-independent disposition of ciprofloxacin. Eur J Clin Microbiol 1984;3:363-366.
13. Chien SC, Chow AT, Natarajan J, Williams RR, Wong FA, Rogge MC, et al: Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997;41:1562-1565.
14. Efthymiopoulos C, Bramer SL, Maroli A: Effect of age and gender on the pharmacokinetics of grepafloxacin. Clin Pharmacokinet 1997;33:9-17.
15. Shah A, Lettieri J, Nix D, Wilton J, Heller AH: Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects. Antimicrob Agents Chemother 1995;39:1003-1006.
16. Sorgel F, Naber KG, Mahr G, Gottschalk B, Stephan U, Seelmann R, et al: Gender related distribution of quinolones. Proceedings for the 3rd International Symposium on New Quinolones, Vancouver, Canada. Eur J Clin Microbiol Infect Dis 1991.
17. Sowinski KM, Kays MB: Determination of ciprofloxacin in human serum and urine by HPLC with ultraviolet and fluorescence detection. J Clin Pharm Ther 2004; in press.
18. D'Argenio DZ, Schumitzky A: ADAPT II User's Guide. Los Angeles: University of Southern California, 1992.
19. Akaike H: An information criterion (AIC). Math Sci 1976;153:5-9.
20. Wagner JG: Pharmacokinetics for the Pharmaceutical Scientist. Lancaster, PA: Technomic, 1993.
21. Smith P, Forrest A, Ballow CH, Martin DE, Proulx L: Absolute bioavailability and disposition of (-) and (+) 2′-deoxy-3′-oxa- 4′-thiocytidine (dOTC) following single intravenous and oral doses of racemic dOTC in humans. Antimicrob Agents Chemother 2000;44: 1609-1615.
22. Wingender W, Graefe KH, Gau W, Forster D, Beermann D, Schacht P: Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Microbiol 1984;3:355-359.
23. Crump B, Wise R, Dent J: Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother 1983;24:784-786.
24. Gillette JR: Factors affecting drug metabolism. Ann NY Acad Sci 1971;179:43-66.
25. Bergogne-Berezin E: Clinical role of protein binding of quinolones. Clin Pharmacokinet 2002;41:741-750.
26. Hayakawa H, Takagi K, Takano YF, Kawamura Y, Tsuji A: Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats. J Pharm Pharmacol 2002;54:1229-1236.
27. Cakmakci M, Gossweiler L, Schilling J, Schlumpf R, Geroulanos S: Penetration of fleroxacin into human lung, muscle, and fat tissue. Drugs Exp Clin Res 1992;18:299-302.
28. Mertes PM, Voiriot P, Dopff C, Scholl H, Clavey M, Villemot JP, et al: Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans. Antimicrob Agents Chemother 1990;34:398-401.
29. Fong IW, Ledbetter WH, Vandenbroucke AC, Simbul M, Rahm V: Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicrob Agents Chemother 1986;29:405-408.
30. Chow AT, Fowler C, Williams RR, Morgan N, Kaminski S, Natarajan J: Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother 2001;45:2122-2125.
31. Gallicano K, Sahai J: Lack of gender effect on ciprofloxacin pharmacokinetics in humans. Br J Clin Pharmacol 1996;42:632-634.
32. Sorgel F, Naber KG, Kinzig M, Mahr G, Muth P: Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review. Am J Med 1991;91:51S-66S.
33. Wilson K: Sex-related differences in drug disposition in man. Clin Pharmacokinet 1984;9:189-202.
34. Gau W, Kurz J, Petersen U, Ploschke HJ, Wuensche C: Isolation and structural elucidation of urinary metabolites of ciprofloxacin. Arzneimittelforschung 1986;36:1545-1549.
35. McLellan RA, Drobitch RK, Monshouwer M, Renton KW: Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 1996;24:1134-1138.
36. Harris RZ, Benet LZ, Schwartz JB: Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50:222-239.
37. Rohwedder R, Bergan T, Thorsteinsson SB, Scholl H: Transintestinal elimination of ciprofloxacin. Chemotherapy 1990;36:77-84.
38. Cavet ME, West M, Simmons NL: Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 1997;121:1567-1578.
39. Dautrey S, Felice K, Petiet A, Lacour B, Carbon C, Farinotti R: Active intestinal elimination of ciprofloxacin in rats: modulation by different substrates. Br J Pharmacol 1999;127:1728-1734.
40. Jaehde U, Sorgel F, Reiter A, Sigl G, Naber KG, Schunack W: Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin Pharmacol Ther 1995;58:532-541.
41. Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, Suzuki N, et al: Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein. J Pharm Pharmacol 2001;53:699-709.
42. Lowes S, Simmons NL: Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 2002;135:1263-1275.
43. Schuetz EG, Furuya KN, Schuetz JD: Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995;275:1011-1018.
44. Kato Y, Kuge K, Kusuhara H, Meier PJ, Sugiyama Y: Gender difference in the urinary excretion of organic anions in rats. J Pharmacol Exp Ther 2002;302:483-489.
45. Cummins CL, Wu CY, Benet LZ: Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002;72:474-489.